Usmani, Omar Sharif
Lavorini, Federico
Marshall, Jonathan
Dunlop, William Christopher Nigel
Heron, Louise
Farrington, Emily
Dekhuijzen, Richard
Funding for this research was provided by:
Mundipharma International Ltd (n/a)
Article History
Received: 7 September 2017
Accepted: 21 December 2017
First Online: 16 January 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: In the last 5 years, Omar S. Usmani and/or his department received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from Aerocrine, Astra Zeneca, Boehringer Ingelheim, Chiesi, Cipla, Edmond Pharma, GlaxoSmithKline, Napp, Mundipharma International, Prosonix, Sandoz, Takeda, Zentiva.In the last 5 years, Federico Lavorini received fees for lectures and advisory board meetings from Astra Zeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini International, TEVA, Zentiva.In the last 3 years, Richard Dekhuijzen and/or his department received research grants, unrestricted educational grants, and/or fees for lectures and advisory board meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma International, Novartis, Takeda and Teva.William Dunlop and Jonathan Marshall are employees of Mundipharma International Ltd., United Kingdom.Emily Farrington and Louise Heron are employees of Adelphi Values Ltd., UK. Adelphi Values Ltd. received funding from Mundipharma International Ltd. to support this research.The authors do not report any conflict of interest with regards to the contents of this study other than those stated.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.